Wavemaker Three-Sixty Health

General Partners Jay Goss and Eric Marton lead the firm's investment committee. Goss was previously a managing director at a healthcare accelerator and brings operator experience in health tech startups. Marton has a background in corporate healthcare development. Dr. Steven Burrill joined as Venture Partner in 2022 and advises on portfolio strategy and healthcare system relationships, but final investment authority rests with the General Partners.

The firm relies on relationships within health system innovation centers, payer strategy groups, and clinical leadership networks rather than traditional accelerator demo-day pipelines. Its narrow mandate — exclusively enterprise health IT — means a high proportion of deals reach the firm through repeat co-investors and founder referrals from within its existing portfolio.

No. The firm explicitly limits its scope to digital health — software and AI-enabled services sold into healthcare enterprises. It does not invest in biotech, pharmaceutical development, medical devices, or diagnostics. This exclusion is structural, not circumstantial, and distinguishes it from hybrid health funds that allocate across both technology and life sciences.

Wavemaker Three-Sixty Health operates as a distinct, US-headquartered fund focused exclusively on healthcare IT, while Wavemaker Partners is a multi-sector venture firm with roots in Los Angeles and Singapore. The two share branding and some limited partner overlap, but the health fund makes its own investment decisions independently and maintains a separate portfolio.

The firm invests at seed and Series A, typically as a lead or co-lead in rounds under $10 million. It reserves capital for follow-on investments in its strongest portfolio companies, but does not operate a growth-stage vehicle. Initial check sizes are not publicly disclosed.